Compliance to treatment guidelines and survival in women undergoing interval debulking surgery for advanced epithelial ovarian cancer

被引:2
|
作者
Shylasree, Thumkur S. [1 ]
Kattepur, Abhay K. [1 ]
Gupta, Monisha [1 ]
Ghosh, Jaya [2 ]
Maheshwari, Amita [1 ]
Bajpai, Jyoti [2 ]
Hawaldar, Rohini [3 ]
Gulia, Seema [2 ]
Deodhar, Kedar [4 ]
Popat, Palak [5 ]
Gupta, Sudeep [2 ]
Kerkar, Rajendra A. [1 ]
机构
[1] Tata Mem Hosp, Dept Gynecol Oncol, Mumbai, Maharashtra, India
[2] Tata Mem Hosp, Dept Med Oncol, Mumbai, Maharashtra, India
[3] Tata Mem Hosp, Dept Clin Res Methodol & Biostat, Mumbai, Maharashtra, India
[4] Tata Mem Hosp, Dept Pathol, Mumbai, Maharashtra, India
[5] Tata Mem Hosp, Dept Radiodiag, Mumbai, Maharashtra, India
关键词
advanced epithelial ovarian cancer; compliance; deviation; interval debulking surgery; survival; NEOADJUVANT CHEMOTHERAPY; CLINICAL-OUTCOMES; ADHERENCE;
D O I
10.1002/cnr2.1217
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundOne of the primary treatment strategies for advanced epithelial ovarian cancers includes neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) and adjuvant chemotherapy. Compliance to treatment is important to possibly improve outcomes. AimTo audit treatment compliance and its effect on overall survival (OS) and disease free survival (DFS) in women undergoing IDS. Methods and ResultsWomen diagnosed with advanced epithelial ovarian cancer undergoing IDS were included. Details of compliance to chemotherapy and surgery as per standard guidelines were assessed, and correlation with survival was studied. Reasons for protocol deviation at various levels were documented and analysed. A total of 182 patients were included. The total number of deviations was 134 with deviation at any level being 89 (48.9%) and at all levels 5%. Both patient- and treatment-related factors contributed towards deviation. Deviation or noncompliance towards treatment resulted in a significantly reduced 5-year OS (34.4% vs 58.2%; P = .001) compared with compliant patients, which retained its significance on multivariate analysis (P = .024) as well. ConclusionDeviation from treatment guidelines resulted in a significantly lower 5-year OS compared with those who remained treatment compliant. Both patient- and treatment-related factors contributed towards noncompliance and hence towards lower survival.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] OPTIMAL RESIDUAL DISEASE AT PRIMARY DEBULKING SURGERY VERSUS COMPLETE TUMOR RESECTION AT INTERVAL DEBULKING SURGERY IN ADVANCED EPITHELIAL OVARIAN CANCER: A CASE-CONTROL SURVIVAL ANALYSIS
    Ghirardi, V.
    Bizzarri, N.
    Vargiu, V.
    D'Indinosante, M.
    Loverro, M.
    Pasciuto, T.
    Scambia, G.
    Fagotti, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A466 - A466
  • [32] Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
    Lee, Yong Jae
    Lee, Jung-Yun
    Nam, Eun Ji
    Kim, Sang Wun
    Kim, Sunghoon
    Kim, Young Tae
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [33] Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer
    Timmermans, M.
    van der Aa, M. A.
    Lalisang, R., I
    Witteveen, P. O.
    Van de Vijver, K. K.
    Kruitwagen, R. F.
    Sonke, G. S.
    GYNECOLOGIC ONCOLOGY, 2018, 150 (03) : 446 - 450
  • [34] Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
    Sorensen, Sarah Mejer
    Hogdall, Claus
    Mosgaard, Berit Jul
    Dalgaard, Maya Isabella Riise
    Jensen, Mai Partridge
    Fuglsang, Katrine
    Schnack, Tine Henrichsen
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2022, 101 (03) : 334 - 343
  • [35] Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery
    Ataseven, Beyhan
    Luengo, Teresa Gonzalez
    du Bois, Andreas
    Waltering, Kai-Uwe
    Traut, Alexander
    Heitz, Florian
    Alesina, Pier Francesco
    Prader, Sonia
    Meier, Beate
    Schneider, Stephanie
    Koch, Jens-Albrecht
    Walz, Martin
    Groeben, Harald-Thomas
    Nina, Pauly
    Brunkhorst, Violeta
    Heikaus, Sebastian
    Harter, Philipp
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (11) : 3372 - 3379
  • [36] Should neoadjuvant chemotherapy be preferred to an alternative treatment for advanced ovarian cancer: Comparison of neoadjuvant chemotherapy followed by interval debulking surgery and primary debulking surgery in patients with advanced ovarian cancer
    Liu, J.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 176 - 176
  • [37] Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery
    Beyhan Ataseven
    Teresa González Luengo
    Andreas du Bois
    Kai-Uwe Waltering
    Alexander Traut
    Florian Heitz
    Pier Francesco Alesina
    Sonia Prader
    Beate Meier
    Stephanie Schneider
    Jens-Albrecht Koch
    Martin Walz
    Harald-Thomas Groeben
    Pauly Nina
    Violeta Brunkhorst
    Sebastian Heikaus
    Philipp Harter
    Annals of Surgical Oncology, 2018, 25 : 3372 - 3379
  • [38] PROGRESSION FREE SURVIVAL COMPARISON WITH NEOADJUVANT CHEMOTHERAPY AND PRIMARY DEBULKING SURGERY IN ADVANCED EPITHELIAL OVARIAN CANCER
    Lee, Y. J.
    Kim, Y. M.
    Lee, S. H.
    Park, J. Y.
    Suh, D. S.
    Kim, D. Y.
    Kim, J. H.
    Kim, Y. T.
    Nam, J. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1416 - 1416
  • [39] Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer
    Tseng, Jill H.
    Cowan, Renee A.
    Afonso, Anoushka M.
    Zhou, Qin
    Iasonos, Alexia
    Ali, Narisha
    Thompson, Errika
    Sonoda, Yukio
    O'Cearbhaill, Roisin E.
    Chi, Dennis S.
    Abu-Rustum, Nadeem R.
    Roche, Kara Long
    GYNECOLOGIC ONCOLOGY, 2018, 151 (02) : 287 - 293
  • [40] Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer
    Vergote, Ignace
    Amant, Frederic
    Kristensen, Gunnar
    Ehlen, Tom
    Reed, Nick S.
    Casado, Antonio
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S88 - S92